zosurabalpin
Sign in to saveZosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter. It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 790.3624877
Show 4 more facts
- isomeric SMILES
- CN1C(=O)[C@H](CCCCN)N=C(O)[C@H](CCCN)NCc2cccnc2Sc2cccc(-c3ccc(C(=O)O)cc3)c2CN=C(O)[C@@H]1Cc1c[nH]c2ccccc12
- chemical formula
- C₄₃H₅₀N₈O₅S
- canonical SMILES
- CN1C(=O)C(CCCCN)N=C(O)C(CCCN)NCc2cccnc2Sc2cccc(-c3ccc(C(=O)O)cc3)c2CN=C(O)C1Cc1c[nH]c2ccccc12
- Commons category
- Zosurabalpin
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter. It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.
== See also == Clovibactin Novobiocin Teixobactin
Excerpted from Wikipedia’s “zosurabalpin” article, available under the CC BY-SA 4.0 licence.